Accelerate Diagnostics scheduled call to review 2022 second quarter results
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) will host a conference call on August 15, 2022, at 4:30 PM ET to discuss its 2022 second quarter results. This call aims to provide insights into the company's performance and future outlook concerning its innovative diagnostic solutions that address antimicrobial resistance and sepsis. The Accelerate Pheno® and Accelerate Arc™ systems promise significantly faster results than traditional methods, optimizing patient treatment.
- Accelerate Pheno® and Accelerate Arc™ systems offer results 1-2 days faster than existing methods, enhancing patient care.
- Upcoming conference call to elaborate on second quarter performance, indicating transparency and shareholder communication.
- None.
TUCSON, Ariz., July 25, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, August 15, 2022, at 4:30 p.m. Eastern Time to review 2022 second quarter results.
To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until November 15, 2022.
To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 8181593. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference.
A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 5773022 until September 6, 2022.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antimicrobial resistance and sepsis. The Accelerate Pheno® system and Accelerate Arc™ system are designed to reduce the time clinicians must wait to determine the most optimal antibiotic therapy for bacteremic patients. These diagnostic systems are designed to serve clinical laboratories with automated solutions to expedite time to identification and antimicrobial susceptibility test (AST) results directly from positive blood culture samples. Multiple external studies have proven that Accelerate solutions deliver results 1 to 2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient's infection, days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and "ACCELERATE ARC" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2022-second-quarter-results-301590275.html
SOURCE Accelerate Diagnostics, Inc.
FAQ
When is the Accelerate Diagnostics second quarter results conference call?
What is the purpose of the Accelerate Diagnostics conference call?
How can I listen to the Accelerate Diagnostics conference call?
